Polymeric PEG-based bioorthogonal triggers for prodrug activation in breast cancer.

ABSTRACT: Non-toxic prodrugs have proved of great value in medicinal chemistry programmes for cancer, due to their ability to selectively deliver toxic components at tumour sites once they are activated by a localised mechanism. Since activation of the prodrug to afford the toxic drug is a prerequisite for success of the approach, much interest has focused on the localised chemical and enzymatic mechanisms for activating the prodrugs. Bioorthogonal chemistry has positively impacted this area by providing biocompatible reactions that enable on-demand prodrug activation and active drug release. However, to be effective, it is essential that one of the components of the bioorthogonal reaction is localised at the tumour, in order to initiate the on-demand and on-target activation of the prodrug. Polymer

SUBMITTER: Mitry MMA 

PROVIDER: S-EPMC11881796 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature